VIDEO: Several treatments in the pipeline for geographic atrophy

Editor’s note: This is an automatically generated transcript, which has been slightly edited for clarity. Please notify editor@healio.com if there are concerns regarding accuracy of the transcription.

I think this is probably one of the hottest areas in retina right now. And most of the drugs that have been in the pipeline previously and the two that have made it to market are focused on complement inhibition, and certainly some that are currently in the pipeline or in the works such as Annexon’s product are also focused on complement, although at a different location in the pathway. But there are opportunities to also consider other mechanisms of action, which is exciting. Some other companies such as Alkeus have leveraged modified vitamin A and Alexion, which looks at factor D inhibition, are looking at oral routes of administration for their product, which is really different for us as retina specialists. I think I was also really excited about the potential of subretinal gene therapy for geographic atrophy with the Gyroscope pipeline, so it was disappointing when that trial was stopped based on recommendations from their data monitoring committee, but hopefully something in that realm will become a possibility in the future too.